Biotech Market Research – Different Approach To Stay Ahead Of Your Competitor

DelveInsight has launched a new report on ” Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2030 ”.   DelveInsight’s “ Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2030 “  report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends.   Geographies Covered :   United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.   Some of the key Facts: Market analysis study carried out by DI for the period of 2017-2030 shows that the Market size of Atopic Dermatitis was USD 2422 Million in 2017 in the 7MM Market Size of Atopic Dermatitis was estimated to be 1038 USD Millions in 2017 in the United States. In the United States prevalent population of Atopic Dermatitis was found to be 19,460,609 in 2017. As per DelveInsight estimates, ...

DelveInsight has launched a new report on “ Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030 ”.   DelveInsight's " Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030 "  report delivers an in-depth understanding of the Acute Lymphoblastic Leukemia (ALL), historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.   Some key facts of the Report: 1.        The estimated worldwide annual incidence of adult acute lymphoblastic leukemia is about 1 in 100,000. 2.        In 2019, about 5930 new cases of ALL, in which 3280 were males and 2650 were females. 3.        ALL accounts for less than 1% of all new cancer cases, among which 55% are in males, and 45% are in females. 4. ...

  DelveInsight has announced the addition of a new market research report -  Prostate cancer Market Insight, Epidemiology and Market Forecast -2030  to its portfolio.   Key Highlights The total Prostate Cancer prevalent cases in the 7MM were observed to be 6,742,385 in 2017, and are expected to increase during the study period (2017–2030). The US accounted for the highest number of Prostate Cancer prevalent cases, which is expected to increase by 2030. Among all the treatment modalities,  Zytiga  (abiraterone acetate) and  Xtandi  (enzalutamide) are the cornerstone treatments of mCRPC. The overall Prostate Cancer Market Size in the 7MM is anticipated to increase by 2030 owing to positive results of investigational products and a robust pipeline. Key companies like AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hino...

FRAGILE X SYNDROME NEWSLETTER Fragile X Syndrome , a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people suffering from it, is a result of mutation associated with the gene known as FMR1. As per DelveInsight assessments, the market size of Fragile X Syndrome (FXS) in the 7MM was found to be  USD 33.51 Million in 2017 , for the study period, 2017–2028. Top companies involved fuelling the FXS Market are: Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others. Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward. Visit to gain access to our Newsletter:  https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome

(Albany, US)  DelveInsight has launched a new report on Genital Warts Market Insights, Epidemiology and Market Forecast-2030 . DelveInsight’s  ‘ Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast-2030  report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GWs in the United States.   Add caption Some of the key facts of the Report: HPV 6 and 11 cause greater than 90% of genital warts cases in males and females. Approximately 3–4 million cases of genital warts in men occur each year with a peak rate of 500 per 100,000 in the 25–29 year old group. The incidence rate of GWs among all men in the study was 2.35 cases per 1000 person-years, with the highest incidence of 3.43 cases per 1000 person-years observed among men aged 18–30 years. Key benefits of the Report 1. Genital Warts market report covers a descriptive overvie...

An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females. DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, Etiology, Symptoms, Market and Epidemiology. Top companies involved : Tetra Therapeutics , Zynerba Pharmaceuticals , Ovid Therapeutics , Confluence Pharmaceuticals, and Neuren Pharmaceuticals. Have a Copy our Newsletter : https://www.delveinsight.com/whitepaper-newsletter/pompe-disease hashtag

The growth of Duchenne Muscular Dystrophy (DMD)  Market is anticipated to increase because of an increasing incidence of DMD patients as well as the launch of emerging drugs in the 7MM. DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on " Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030 " to its portfolio. Key Highlights from the report are: As per the DelveInsight analysis, the total diagnosed Duchenne Muscular Dystrophy prevalent population in the 7 MM was 27,685 in 2017. The total diagnosed prevalent cases of DMD patients were found to be maximum in the age-group of 8–13 year and 14–19 year in  the United States  in 2017. The treatment for DMD patients is the standard care along with the new upcoming therapeutic strategies covering Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and secondar...